Clinical Performance Evaluation of an Artificial Intelligence‑Powered Amyloid Brain PET Quantification Method
10.1007/s13139-024-00861-6
- Author:
Seung Kwan KANG
1
;
Mina HEO
;
Ji Yeon CHUNG
;
Daewoon KIM
;
Seong A. SHIN
;
Hongyoon CHOI
;
Ari CHUNG
;
Jung‑Min HA
;
Hoowon KIM
;
Jae Sung LEE
Author Information
1. Brightonix Imaging Inc., Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Nuclear Medicine and Molecular Imaging
2024;58(4):246-254
- CountryRepublic of Korea
- Language:English
-
Abstract:
Methods:150 amyloid brain PET images were visually assessed by experts and categorized as negative and positive. Standardized uptake value ratio (SUVR) was calculated with cerebellum grey matter as the reference region, and receiver operating characteristic (ROC) and precision-recall (PR) analysis for BTXBrain-Amyloid were conducted. For comparison, same image processing and analysis was performed using Statistical Parametric Mapping (SPM) program. In addition, to evaluate the spatial normalization (SN) performance, mutual information (MI) between MRI template and spatially normalized PET images was calculated and SPM group analysis was conducted.
Results:Both BTXBrain and SPM methods discriminated between negative and positive groups. However, BTXBrain exhibited lower SUVR standard deviation (0.06 and 0.21 for negative and positive, respectively) than SPM method (0.11 and 0.25). In ROC analysis, BTXBrain had an AUC of 0.979, compared to 0.959 for SPM, while PR curves showed an AUC of 0.983 for BTXBrain and 0.949 for SPM. At the optimal cut-off, the sensitivity and specificity were 0.983 and 0.921 for BTXBrain and 0.917 and 0.921 for SPM12, respectively. MI evaluation also favored BTXBrain (0.848 vs. 0.823), indicating improved SN. In SPM group analysis, BTXBrain exhibited higher sensitivity in detecting basal ganglia differences between negative and positive groups.
Conclusion:BTXBrain-Amyloid outperformed SPM in clinical performance evaluation, also demonstrating superior SN and improved detection of deep brain differences. These results suggest the potential of BTXBrain-Amyloid as a valuable tool for clinical amyloid PET image evaluation.
